India’s Emcure Pharmaceuticals aims to raise $400-500 million from an initial public offering planned for next year, two sources said, reviving listing plans the drugmaker shelved in early 2022 as the Ukraine war roiled global markets.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
